questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Globulines
Sérum-globulines
Immunoglobulines
Anticorps
Autoanticorps
Anticorps antiphospholipides
Anticorps antiphospholipides : Questions médicales fréquentes
Diagnostic
5
Anticorps antiphospholipides
Tests de laboratoire
Anticorps anticardiolipine
Lupus anticoagulant
Surveillance médicale
Antécédents médicaux
Anticorps
Tests de laboratoire
Asymptomatique
Anticorps antiphospholipides
Symptômes
5
Thrombose
Fausses couches
Variabilité des symptômes
Anticorps antiphospholipides
Éruption cutanée
Anticorps antiphospholipides
Événement déclencheur
Symptômes
Prévention
5
Mode de vie sain
Prévention
Grossesse
Surveillance médicale
Vaccination
Consultation médicale
Traitements
5
Anticoagulants
Prévention des thromboses
Corticostéroïdes
Inflammation
Prévention
Anticoagulants
Médecine personnalisée
Antécédents médicaux
Durée du traitement
Événements thromboemboliques
Complications
5
Prévention
Traitement préventif
Réversibilité
Effets durables
Qualité de vie
Complications
Facteurs de risque
5
Antécédents familiaux
Maladies auto-immunes
Infections
Anticorps antiphospholipides
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Anticorps antiphospholipides : Questions médicales les plus fréquentes",
"headline": "Anticorps antiphospholipides : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Anticorps antiphospholipides : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-19",
"dateModified": "2026-07-07",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Anticorps antiphospholipides"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Autoanticorps",
"url": "https://questionsmedicales.fr/mesh/D001323",
"about": {
"@type": "MedicalCondition",
"name": "Autoanticorps",
"code": {
"@type": "MedicalCode",
"code": "D001323",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.323"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Anticorps anticardiolipines",
"alternateName": "Antibodies, Anticardiolipin",
"url": "https://questionsmedicales.fr/mesh/D017153",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps anticardiolipines",
"code": {
"@type": "MedicalCode",
"code": "D017153",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.323.210.100"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Anticorps antiphospholipides",
"alternateName": "Antibodies, Antiphospholipid",
"code": {
"@type": "MedicalCode",
"code": "D017152",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Katrien M J Devreese",
"url": "https://questionsmedicales.fr/author/Katrien%20M%20J%20Devreese",
"affiliation": {
"@type": "Organization",
"name": "Coagulation Laboratory, Ghent University Hospital, Department of Diagnostic Sciences, Ghent University, Ghent, Belgium."
}
},
{
"@type": "Person",
"name": "Savino Sciascia",
"url": "https://questionsmedicales.fr/author/Savino%20Sciascia",
"affiliation": {
"@type": "Organization",
"name": "Center of Research of Immunopathology and Rare Diseases, Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy."
}
},
{
"@type": "Person",
"name": "Stéphane Zuily",
"url": "https://questionsmedicales.fr/author/St%C3%A9phane%20Zuily",
"affiliation": {
"@type": "Organization",
"name": "Université de Lorraine, Inserm, DCAC, Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, Centre Hospitalier Regional Universitaire de Nancy, 54000, Nancy, France."
}
},
{
"@type": "Person",
"name": "Doruk Erkan",
"url": "https://questionsmedicales.fr/author/Doruk%20Erkan",
"affiliation": {
"@type": "Organization",
"name": "Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery and Weill Cornell Medicine, 535 E. 70th St., 6th floor, New York, NY, 10021, USA. Electronic address: erkand@hss.edu."
}
},
{
"@type": "Person",
"name": "Jason S Knight",
"url": "https://questionsmedicales.fr/author/Jason%20S%20Knight",
"affiliation": {
"@type": "Organization",
"name": ""
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Non-criteria antiphospholipid antibodies and calprotectin as potential biomarkers in pediatric antiphospholipid syndrome.",
"datePublished": "2024-02-13",
"url": "https://questionsmedicales.fr/article/38355030",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.clim.2024.109926"
}
},
{
"@type": "ScholarlyArticle",
"name": "16th International congress on antiphospholipid antibodies task force report on antiphospholipid syndrome laboratory diagnostics and trends.",
"datePublished": "2023-11-07",
"url": "https://questionsmedicales.fr/article/37933818",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1177/09612033231211820"
}
},
{
"@type": "ScholarlyArticle",
"name": "The clinical relevance of different antiphospholipid antibody profiles in pediatric rheumatology patients.",
"datePublished": "2024-04-26",
"url": "https://questionsmedicales.fr/article/38671480",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12969-024-00954-8"
}
},
{
"@type": "ScholarlyArticle",
"name": "Haematological and other manifestations in the presence of antiphospholipid antibodies in a multicentric paediatric cohort.",
"datePublished": "2023-09-08",
"url": "https://questionsmedicales.fr/article/37706308",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.55563/clinexprheumatol/3mzh06"
}
},
{
"@type": "ScholarlyArticle",
"name": "Thrombotic risk assessment in antiphospholipid syndrome: do noncriteria antibodies contribute?",
"datePublished": "2023-09-13",
"url": "https://questionsmedicales.fr/article/38813003",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.55730/1300-0144.5671"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Globulines",
"item": "https://questionsmedicales.fr/mesh/D005916"
},
{
"@type": "ListItem",
"position": 5,
"name": "Sérum-globulines",
"item": "https://questionsmedicales.fr/mesh/D012712"
},
{
"@type": "ListItem",
"position": 6,
"name": "Immunoglobulines",
"item": "https://questionsmedicales.fr/mesh/D007136"
},
{
"@type": "ListItem",
"position": 7,
"name": "Anticorps",
"item": "https://questionsmedicales.fr/mesh/D000906"
},
{
"@type": "ListItem",
"position": 8,
"name": "Autoanticorps",
"item": "https://questionsmedicales.fr/mesh/D001323"
},
{
"@type": "ListItem",
"position": 9,
"name": "Anticorps antiphospholipides",
"item": "https://questionsmedicales.fr/mesh/D017152"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Anticorps antiphospholipides - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Anticorps antiphospholipides",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-08-31",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Anticorps antiphospholipides",
"description": "Comment diagnostiquer les anticorps antiphospholipides ?\nQuels tests sont utilisés pour le diagnostic ?\nQuelle est la fréquence des tests pour ces anticorps ?\nLes anticorps antiphospholipides sont-ils toujours présents ?\nPeut-on avoir des anticorps sans symptômes ?",
"url": "https://questionsmedicales.fr/mesh/D017152#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Anticorps antiphospholipides",
"description": "Quels sont les symptômes des anticorps antiphospholipides ?\nLes symptômes varient d'une personne à l'autre ?\nComment se manifestent les thromboses ?\nLes éruptions cutanées sont-elles fréquentes ?\nLes symptômes peuvent-ils apparaître soudainement ?",
"url": "https://questionsmedicales.fr/mesh/D017152#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Anticorps antiphospholipides",
"description": "Comment prévenir les complications liées aux anticorps ?\nLes changements de mode de vie aident-ils ?\nFaut-il éviter certains médicaments ?\nLes femmes enceintes doivent-elles être surveillées ?\nLes vaccinations sont-elles sûres ?",
"url": "https://questionsmedicales.fr/mesh/D017152#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Anticorps antiphospholipides",
"description": "Quel est le traitement principal pour ces anticorps ?\nLes corticostéroïdes sont-ils utilisés ?\nY a-t-il des traitements préventifs ?\nLes traitements sont-ils personnalisés ?\nCombien de temps dure le traitement ?",
"url": "https://questionsmedicales.fr/mesh/D017152#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Anticorps antiphospholipides",
"description": "Quelles sont les complications possibles ?\nLes AVC sont-ils fréquents ?\nLes complications peuvent-elles être évitées ?\nLes complications sont-elles réversibles ?\nLes complications affectent-elles la qualité de vie ?",
"url": "https://questionsmedicales.fr/mesh/D017152#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Anticorps antiphospholipides",
"description": "Quels sont les facteurs de risque associés ?\nLe sexe influence-t-il le risque ?\nL'obésité est-elle un facteur de risque ?\nLes infections peuvent-elles déclencher des anticorps ?\nLe stress a-t-il un impact sur le risque ?",
"url": "https://questionsmedicales.fr/mesh/D017152#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer les anticorps antiphospholipides ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un diagnostic se fait par des tests sanguins spécifiques pour détecter ces anticorps."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests d'anticorps anticardiolipine et de lupus anticoagulant sont courants."
}
},
{
"@type": "Question",
"name": "Quelle est la fréquence des tests pour ces anticorps ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "La fréquence dépend des symptômes et des antécédents médicaux, souvent tous les 6 mois."
}
},
{
"@type": "Question",
"name": "Les anticorps antiphospholipides sont-ils toujours présents ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, ils peuvent être intermittents et ne sont pas toujours détectables."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des anticorps sans symptômes ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines personnes peuvent avoir des anticorps sans présenter de symptômes cliniques."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes des anticorps antiphospholipides ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des thromboses, des fausses couches et des éruptions cutanées."
}
},
{
"@type": "Question",
"name": "Les symptômes varient d'une personne à l'autre ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier considérablement selon les individus et les cas."
}
},
{
"@type": "Question",
"name": "Comment se manifestent les thromboses ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les thromboses peuvent se manifester par des douleurs, un gonflement ou une rougeur."
}
},
{
"@type": "Question",
"name": "Les éruptions cutanées sont-elles fréquentes ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les éruptions cutanées sont moins fréquentes mais peuvent survenir chez certains patients."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils apparaître soudainement ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent apparaître soudainement, souvent après un événement déclencheur."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications liées aux anticorps ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention inclut l'utilisation d'anticoagulants et un suivi médical régulier."
}
},
{
"@type": "Question",
"name": "Les changements de mode de vie aident-ils ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sain, comme l'exercice et une alimentation équilibrée, aide à prévenir."
}
},
{
"@type": "Question",
"name": "Faut-il éviter certains médicaments ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments peuvent augmenter le risque de thrombose et doivent être évités."
}
},
{
"@type": "Question",
"name": "Les femmes enceintes doivent-elles être surveillées ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les femmes enceintes avec ces anticorps doivent être étroitement surveillées."
}
},
{
"@type": "Question",
"name": "Les vaccinations sont-elles sûres ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la plupart des vaccinations sont sûres, mais consultez un médecin avant."
}
},
{
"@type": "Question",
"name": "Quel est le traitement principal pour ces anticorps ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement principal inclut des anticoagulants pour prévenir les thromboses."
}
},
{
"@type": "Question",
"name": "Les corticostéroïdes sont-ils utilisés ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les corticostéroïdes peuvent être utilisés pour réduire l'inflammation dans certains cas."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements préventifs ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements préventifs incluent des anticoagulants à long terme pour les patients à risque."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements sont souvent personnalisés en fonction des symptômes et des antécédents."
}
},
{
"@type": "Question",
"name": "Combien de temps dure le traitement ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "La durée du traitement dépend de la gravité et de la fréquence des événements thromboemboliques."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des thromboses veineuses profondes, des AVC et des fausses couches."
}
},
{
"@type": "Question",
"name": "Les AVC sont-ils fréquents ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les AVC sont une complication sérieuse et peuvent survenir chez les patients affectés."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être évitées ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être évitées avec un traitement préventif approprié."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles, mais d'autres peuvent avoir des effets durables."
}
},
{
"@type": "Question",
"name": "Les complications affectent-elles la qualité de vie ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications peuvent significativement affecter la qualité de vie des patients."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque associés ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, des maladies auto-immunes et le tabagisme."
}
},
{
"@type": "Question",
"name": "Le sexe influence-t-il le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les femmes sont plus souvent affectées que les hommes, surtout en âge de procréer."
}
},
{
"@type": "Question",
"name": "L'obésité est-elle un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'obésité augmente le risque de complications thromboemboliques."
}
},
{
"@type": "Question",
"name": "Les infections peuvent-elles déclencher des anticorps ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections peuvent déclencher la production d'anticorps antiphospholipides."
}
},
{
"@type": "Question",
"name": "Le stress a-t-il un impact sur le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut influencer le risque de développer des anticorps antiphospholipides."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 07/07/2026
Contenu vérifié selon les dernières recommandations médicales
8 publications dans cette catégorie
Affiliations :
Coagulation Laboratory, Ghent University Hospital, Department of Diagnostic Sciences, Ghent University, Ghent, Belgium.
5 publications dans cette catégorie
Affiliations :
Center of Research of Immunopathology and Rare Diseases, Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy.
Nephrology and Dialysis Unit, S. Giovanni Bosco Hospital and University of Turin, Turin, Italy.
Publications dans "Anticorps antiphospholipides" :
4 publications dans cette catégorie
Affiliations :
Université de Lorraine, Inserm, DCAC, Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, Centre Hospitalier Regional Universitaire de Nancy, 54000, Nancy, France.
Publications dans "Anticorps antiphospholipides" :
4 publications dans cette catégorie
Affiliations :
Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery and Weill Cornell Medicine, 535 E. 70th St., 6th floor, New York, NY, 10021, USA. Electronic address: erkand@hss.edu.
Publications dans "Anticorps antiphospholipides" :
4 publications dans cette catégorie
Publications dans "Anticorps antiphospholipides" :
3 publications dans cette catégorie
Affiliations :
Center of Research of Immunopathology and Rare Diseases, Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy.
Publications dans "Anticorps antiphospholipides" :
3 publications dans cette catégorie
Affiliations :
Faculty of medical and health science, Tel Aviv University, Tel Aviv, Israel; Clinical Immunology, Angioedema, and Allergy Institute, Center for autoimmune Diseases, Sheba Medical Center, Ramat-Gan, Israel.
Publications dans "Anticorps antiphospholipides" :
3 publications dans cette catégorie
Affiliations :
Department of Hematology, CHU Nîmes, Univ Montpellier, Nîmes, France.
Debrest Institute of Epidemiology and Public Health, Univ Montpellier, INSERM, Montpellier, France.
Department of Obstetrics, Gynecology and Perinatal Medicine, I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation.
Publications dans "Anticorps antiphospholipides" :
3 publications dans cette catégorie
Affiliations :
a Rheumatology Unit, Department of Medicine , University Hospital of Padua , Padua , Italy.
Publications dans "Anticorps antiphospholipides" :
3 publications dans cette catégorie
Affiliations :
a Rheumatology Unit, Department of Medicine , University Hospital of Padua , Padua , Italy.
Publications dans "Anticorps antiphospholipides" :
3 publications dans cette catégorie
Affiliations :
a Rheumatology Unit, Department of Medicine , University Hospital of Padua , Padua , Italy.
Publications dans "Anticorps antiphospholipides" :
3 publications dans cette catégorie
Affiliations :
a Rheumatology Unit, Department of Medicine , University Hospital of Padua , Padua , Italy.
Publications dans "Anticorps antiphospholipides" :
3 publications dans cette catégorie
Publications dans "Anticorps antiphospholipides" :
3 publications dans cette catégorie
Affiliations :
Division of Vascular Medicine, Regional Competence Centre for Rare Vascular and Systemic Autoimmune Diseases, Nancy Academic Hospital, Nancy, France.
Inserm UMR_S 1116, Lorraine University, Nancy, France.
Publications dans "Anticorps antiphospholipides" :
3 publications dans cette catégorie
Publications dans "Anticorps antiphospholipides" :
2 publications dans cette catégorie
Affiliations :
Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.
Haemostasis Research Unit, Department of Haematology, University College London, London, UK.
Publications dans "Anticorps antiphospholipides" :
2 publications dans cette catégorie
Affiliations :
AO Ordine Mauriziano, Turin, Italy.
Publications dans "Anticorps antiphospholipides" :
2 publications dans cette catégorie
Affiliations :
Center of Research of Immunopathology and Rare Diseases, Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy.
Nephrology and Dialysis Unit, S. Giovanni Bosco Hospital and University of Turin, Turin, Italy.
Publications dans "Anticorps antiphospholipides" :
2 publications dans cette catégorie
Affiliations :
Department of Hematology, CHU Nîmes, Univ Montpellier, Nîmes, France.
Debrest Institute of Epidemiology and Public Health, Univ Montpellier, INSERM, Montpellier, France.
Publications dans "Anticorps antiphospholipides" :
2 publications dans cette catégorie
Affiliations :
Department of Hematology, CHU Nîmes, Univ Montpellier, Nîmes, France.
Debrest Institute of Epidemiology and Public Health, Univ Montpellier, INSERM, Montpellier, France.
Publications dans "Anticorps antiphospholipides" :
Our study aimed to evaluate the presence, clinical associations, and potential mechanistic roles of non-criteria antiphospholipid antibodies (aPL) and circulating calprotectin, a highly stable marker ...
Classification criteria for antiphospholipid syndrome (APS) require IgG or IgM isotypes of the anticardiolipin (aCL) antibodies, anti-β2 glycoprotein I (anti-β2GPI) antibodies, and/or the lupus antico...
The clinical relevance of different antiphospholipid antibody (aPL) profiles, including low level anticardiolipin (aCL) and anti-β...
In this single center retrospective cohort study, based on the screening of our pediatric (age ≤ 18) rheumatology electronic medical records (2016-2022), we identified patients who had at least one "p...
An initial high-risk aPL profile was persistent in approximately 90% of our cohort, a third of whom had thrombosis, and half had non-thrombotic aPL manifestations. Our results underscore the need for ...
To identify the variables associated with the development of haematological manifestations in the presence of antiphospholipid antibodies (aPLs) in a paediatric cohort....
We conducted a multicentric retrospective cohort study of children under the age of 18 years....
One hundred and thirty-four children were included; 12.2% had at least one thrombotic event (TE) and 67% at least one non-criterion manifestation. Of them, 90% did not develop any TE. Haematological m...
Non-criteria manifestations and among them haematological disorders, are the most frequent events in the presence of aPLs and/or LA in our paediatric cohort. Children with SLE, LA and/or IgG aβ2GPI po...
In this cross-sectional study, it was aimed to test the predictive value of noncriteria antiphospholipid antibodies (aPL) in addition to the global antiphospholipid syndrome score (GAPSS) in predictin...
This study included 50 patients with primary APS, 68 with SLE/APS, and 52 with aPL (+) SLE who were classified according to VT as VT ± pregnancy morbidity (PM), PM only or aPL (+) SLE. Antiphospholipi...
The mean GAPSS and aGAPSS of the study population were 11.6 ± 4.4 and 9.6 ± 3.8. Both the VT ± PM APS (n = 105) and PM only APS (n = 13) groups had significantly higher GAPSS and aGAPSS values compare...
Both the GAPSS and aGAPSS successfully predict the thrombotic risk in aPL (+) patients and aCL IgA, aβ2GPI IgA, and aDI IgG do not contribute to high a GAPSS or aGAPSS....
Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by the presence of antiphospholipid antibodies (aPLs), which can lead to thrombosis and pregnancy complications. Within the dive...
Thrombosis is a unique complication of coronavirus disease 2019 (COVID-19). Although antiphospholipid antibodies (aPL) are detected in COVID-19 patients, their clinical significance remains elusive. W...
This retrospective single-center nested case-control study included 594 hospitalized patients with COVID-19 between January 2020 and August 2021. Thrombotic complications were collected from medical r...
Among the patients, 31 patients with thrombosis and 62 patients without were compared. The prevalence of any aPLs was indifferent regardless of the thrombosis (41.9% in those with thrombosis...
Although aPLs were frequently detected in Japanese COVID-19 patients, their prevalence and titer were irrelevant to thrombotic complications. While COVID-19 patients have lower levels of serum β2GPI t...
Valvular heart disease (VHD) is a prevalent cardiac manifestation in antiphospholipid syndrome (APS) patients. However, risk factors and predictors for antiphospholipid antibody-associated VHD (aPL-VH...
This meta-analysis assesses antiphospholipid antibodies' (aPLs) impact on heart valve disease in Systemic Lupus Erythematosus (SLE) patients. We searched PubMed, Embase, Cochrane, and Web of Science u...
The relationship between antiphospholipid syndrome (APS) and acute viral infection, such as SARS-CoV-2, is unclear. This study aims to assess symptoms, antiphospholipid antibody (aPL) fluctuations, an...